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Abstract
The production of type I interferons (IFNs) in response to viral infections is critical for antiviral immunity. However, IFN
production is transient, and continued expression can lead to inflammatory or autoimmune diseases. Thus, understanding
the mechanisms underlying the negative regulation of IFN expression could lead to the development of novel therapeutic
approaches to the treatment of these diseases. We report that the transcription factor IRF3 plays a central role in the
negative regulation of interferon-b (IFNb) expression during both acute and persistent (chronic) virus infections. We show
that the degradation of IRF3 during acute infections, rather than the activation of transcriptional repressors, leads to the
down regulation of IFNb expression. We also show that the block to IFNb expression in mouse embryonic fibroblasts that
are persistently infected with Sendai virus (SeV) correlates with the absence of transcriptionally active IRF3. Remarkably,
ongoing protein synthesis and viral replication are required to maintain repression of the IFNb gene in persistently infected
cells, as the gene can be activated by the protein synthesis inhibitor cycloheximide, or by the antiviral drug ribavirin. Finally,
we show that the SeV V protein inhibits IRF3 activity in persistently infected cells. Thus, in conjunction with the known
interference with STAT1 by the SeV C protein, both IFN activation and its signaling pathways are blocked in persistently
infected cells. We conclude that the transcription factor IRF3 is targeted for turnover and inactivation through distinct
mechanisms from both the host cells and virus, leading to the inhibition of IFNb gene expression during acute and
persistent viral infections. These observations show that IRF3 plays a critical role, not only in the activation of the IFNb gene,
but also in the controlling the duration of its expression. (284 words)
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Introduction
Virus infection induces the transient expression of type I
interferons (IFNs) in virtually every cell type [1]. Secreted IFNs
bind to cell surface receptors in both the infected and surrounding
cells to induce antiviral activities encoded by interferon stimulated
genes (ISGs). IFNs also coordinate the activation of the adaptive
immune system, which is necessary to control the spread of
infection [1,2,3].
Regulation of interferon-b (IFNb) gene expression has been
extensively studied [4,5], and the regulatory sequences, critical
transcription factors and components of the virus-induced
signaling pathway identified [6]. Viral RNA is detected by RIG-
I and MDA5 in most cells [7]. Both proteins undergo a
conformational change upon binding to a 59-triphosphate
panhandle RNA or long double stranded RNAs (dsRNAs)
associated with virus infection and replication [8,9]. This
conformational change leads to homodimerization of the RNA
sensors, and signal transmission through a critical adaptor protein
MAVS located on the mitochondrial membrane [10,11]. This
interaction requires caspase-recruiting domains (CARD) on both
the RNA sensors and MAVS [11,12,13,14]. Once engaged with
RIG-I or MDA5, the MAVS complex recruits the downstream
adaptor proteins TRAF3 and TRAF6, and the kinases TBK1
[12,15] and IKKa/b [11,13], leading to the activation of the
critical transcription factors IRF3/7 and NFkB. Phosphorylated
IRF3/7 and NFkB translocate into the nucleus, and together with
cJUN/ATF2 and the transcriptional coactivators CBP/p300 form
an enhanceosome complex upstream of the IFNb gene promoter
[4]. Chromatin remodeling factors and the basic transcription
machinery are then recruited to drive the expression of the gene
[16].
The production of IFN is essential for countering virus
infections, but IFN gene expression must be tightly regulated.
The continued expression of IFN is toxic, and over-expression can
contribute to inflammatory and autoimmune diseases [17,18,19].
Thus, tight regulation of the level and duration of IFN expression
is necessary to mount a strong antiviral response on the one hand,
while preventing the negative effects of IFN overproduction on the
other.
A number of proteins that negatively regulate IFN expression
have been identified, and virtually every component in the virus
induction signaling pathway is controlled by either host or viral
proteins. For example, the RIG-I protein is down regulated by the
host protein RFN125, CYLD, NLRC5, Casein kinase II and other
kinases [20,21,22,23,24,25]; the MAVS protein is also negatively
regulated by the host proteins NLRX1 and PCBP2 [26,27], and is
cleaved from the mitochondria surface by the NS3/4 protease of
the hepatitis C virus (HCV) [28]. Moreover, the adaptor proteins
TRAF3 and TRAF6 are targeted by the cellular proteins DUBA
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transcription activator IRF3 is under negative regulation by host
protein Pin1 and MafB, and HIV accessory proteins VPR and Vif
[32,33,34], and the p65 subunit of NFkB is targeted for
degradation by PDLIM2 [35]. All of these proteins suppress IFNb
gene expression.
A common feature of these negative regulators of the virus
infection signaling pathway is that their ability to inhibit or
enhance expression of IFNb correlates with their increased or
reduced expression, respectively. However, it is important to note
that none of these factors are required to turn off IFNb expression
following virus infection. Thus, the mechanisms of post-induction
termination of IFNb expression are largely unknown. The IFNb
gene is transiently expressed in response to viral infection. In most
cultured cells, IFNb gene transcripts are typically detected within
3–6 hrs after infection, peak at 9–12 hrs and return to base line by
24 hrs [36,37]. In animals, expression of the IFNb gene is also
turned-off a few days after virus infection [38,39]. Thus, it appears
that switching off IFNb gene expression during the time course of
virus infection is an integral part of the innate immunity regulatory
mechanism.
Early studies established that the post-induction turn-off of
IFNb gene expression is primarily at the level of transcription and
not mRNA turnover [37]. However, the question of whether the
termination of IFNb transcription is due to the inactivation of
transcriptional activators or the induction of repressors or the
combination of both has not been answered. We have therefore
investigated the mechanisms of post-induction turn-off of IFNb
gene expression during acute virus infection.
Viruses have evolved the ability to suppress IFN gene expression
to avoid the antiviral response and either continue lytic growth or
establish a persistent (chronic) infection. For example, both the
hepatitis C virus (HCV) [40,41] and the human immunodeficiency
virus (HIV) [42,43] establish persistent infections, and therefore
pose major challenges to human health. Similarly, lymphocytic
choriomeningitis virus (LCMV) can establish persistent infection in
the mouse central nervous and immune systems [44,45], and
Sendai virus is also able to establish persistent infections in mouse
respiratory tissues [46]. The infecting virus enters the persistent
state by either high replication or latency. The former is associated
with active viral replication in infected hosts, and virus products
inhibit the host immune responses [47]. In the case of the latent
response the virus persists in a quiescent state, but can reactivate
replication under appropriate circumstances [47]. Persistent viral
infection poses a great threat to human health, as uncontrolled
viral replication will exhaust host resources and lead to cell death;
the impaired host immune response also makes infected
individuals highly vulnerable to opportunistic infection [47].
The controlof virusreplication inpersistently infected individuals
has been the focus of many studies, but the role of IFN in persistent
infection has not been determined. In principle, the antiviral effects
of IFN should suppress persistent infections. In fact, persistently
infected HCV patients have been shown to benefit from IFN
treatment [48]. However, when HIV infected patients were treated
with IFN no effect on virus replication was observed, and IFN was
detected in the serum of HIV patients not treated with IFN [49,50].
In addition, prolonged IFN production in AIDS patients appears to
contribute to the transition from persistent to pathogenic HIV
infection [50,51]. Consistent with this possibility, recent studies
showed that a primary difference between non-pathogenic and
pathogenic AIDS virus infection is the duration of the expression of
IFNand the inducedISGs:asustainedexpressionofthesegeneswas
observed in pathogenic infections, in contrast to a transient
expression in non-pathogenic infections [38,39].
Here we present the results of a study of the negative regulation
of IFN expression during acute SeV infection and in a cellular
model of SeV persistent infection. In both cases we show that the
transcription factor IRF3 is a key protein targeted for negative
regulation of IFNb expression. Our studies point to the regulation
of IRF3 as a critical factor in the prevention of virus-induced
diseases.
Results
The role of IRF3 degradation in the post-induction turn-
off of IFNb expression
While the activation of IFNb gene expression by virus infection
is well understood, its turn-off is not. Previous studies have shown
that the post-induction decrease in IFNb gene expression occurs at
the level of transcription [37]: nuclear run-on assays measuring the
transcription rate revealed that the decrease of IFNb mRNA
coincides with the termination of transcription. Treatment of
virus-infected cells with cycloheximide (CHX) (an inhibitor of
protein synthesis) prevents the turn-off of IFNb transcription, and
also stabilizes the steady state level of the IFNb mRNA. Two
models have been proposed to explain this data: In the repressor
model, newly synthesized repressor(s) (whose synthesis is blocked
by CHX treatment) competes with transcriptional activators for
binding to the IFNb promoter, and when bound maintains the
promoter in an ‘‘off’’ state. In the second model the transcriptional
activators required for IFNb gene expression are down regulated,
and the required regulatory proteins cannot be synthesized in the
presence of CHX. Which of these models is correct is not known.
We first studied whether the inactivation of transcription factors
is the primary mechanism for IFNb turn-off. We monitored the
expression of key transcription factors during the normal time
course of virus infection, as well as infection in the presence of
CHX, which prevents the post-induction turn-off of IFNb gene
expression.
IRF3, which is an essential transcriptional activator of the IFNb
gene, has been shown to undergo virus-induced phosphorylation
and subsequent degradation [52,53]. However, the nature of the
degradation has not been fully defined, and its role in IFNb turn-
off has not been established. We first monitored the IRF3 protein
levels in mouse embryonic fibroblasts (MEF) infected with Sendai
virus (SeV) in the presence or absence of CHX. As previously
shown [52,53], IRF3 undergoes virus-induced degradation, and
after 24 hrs infection, relatively little IRF3 protein could be
detected (Fig. 1A). By contrast, in the presence of CHX the level of
IRF3 did not change during the time course of infection (Fig. 1A).
The levels of IRF3 in the absence or presence of CHX correlate
well with the turn-off or continued expression of the IFNb gene
(Fig. 1A, bottom panel). Thus, the degradation of IRF3 during
virus infection is likely to play a key role in the turn-off of IFNb
expression. Additional experiments showed that the level of the
NFkB p65 subunit was unaffected during virus infection, and the
level of IRF7 was induced 6 hrs after virus infection (the IRF7
antibody cross-reacts with another protein, IRF7 is seen as a more
rapidly migrating faint band). Only a slight decrease in IRF7
protein was observed 24 hr post-infection, in contrast to the major
degradation of IRF3 (Fig. 1A). Thus, IRF3 appears to be unique
among the transcription factors required for IFN expression with
respect to post-induction turnover.
To exclude the possibility that the post-induction degradation of
IRF3 occurs only in murine cells, we also monitored the levels of
IRF3 in human cells after SeV infection. As shown in Figure 1B,
CHX abolished the virus-induced degradation of IRF3 in human
MG63 cells, and as a result, sustained expression of IFNb was
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CHX induced much higher levels of phosphorylated IRF3
compared to that observed with virus or CHX alone (Fig. 1B).
This increase could contribute to the ‘‘super-induction’’ of IFN
reported in earlier studies [37]. Importantly, IRF3 turn-over was
not observed after 24 hrs of infection in the presence of CHX, in
direct contrast to the degradation of IRF3 observed in cells
infected by SeV in the absence of CHX (Fig. 1B). Thus, CHX
inhibits the virus-induced degradation of IRF3 protein in both
MEFs and MG63 cells, and as a result, IFNb expression continues.
By contrast, IFNb turn-off is slower in human Namalwa cells
(Fig. 1B top panel). We note that virus infection also induced some
degradation of IRF3 in Namalwa cells, but, the level of the
phosphorylated IRF3 remained high as late as 24 hrs post-
infection (Fig. 1B). As with the other cell lines, CHX abolished
IRF3 turnover. Taken together with previous observations [37],
these data strongly suggest that the degradation of phosphorylated
(activated) IRF3 protein is a primary mechanism for the
transcriptional turn-off of the IFNb gene during acute virus
infections.
In previous studies the virus-induced degradation of IRF3 was
shown to depend on the ubiquitin-proteosome system [52,53]. We
therefore tested the effects of the proteosome inhibitor MG132 on
the degradation of IRF3 and subsequent IFNb turn-off. Consistent
with previous reports, MG132 treatment did lead to accumulation
of phosphorylated IRF3 in MEFs (Fig. 1C). Surprisingly, however,
the degradation of IRF3 was only partially inhibited by MG132
treatment. The effects were stronger with shorter SeV infection
(8 hrs post infection, Fig. 1C). However, significant degradation of
IRF3 was also observed at 24 hours after infection (Fig. 1C), and
as a result, the expression of the IFNb gene was still turned-off
(Fig. 1C top panel). Higher concentrations of MG132 (50 mM)
inhibited the activation of the IFNb gene (Fig. 1C), most likely due
to blocking the degradation of IKBa, the inhibitor of NFkB [54],
as demonstrated by its inhibition of TNF induced IKBa
degradation (Fig. S1A). Significant degradation of IRF3 was
similarly observed 24 hours after SeV infection in the presence of
lactacystin, another specific proteosome inhibitor (Fig. S1B). Thus,
our data clearly show that the ubiquitin-proteosome system is not
sufficient to completely inactivate IRF3. Other inducible proteases
Figure 1. The degradation of IRF3 correlates with the turn-off of IFNb expression. A. Virus-induced IRF3 degradation is blocked by CHX
treatment. MEFs were treated with SeV and/or CHX for the indicated times. Half of the samples were lysed for total protein extracts and subjected to
western blot analysis, probing for IRF3, IRF7, p65 and b-Actin. RNA was extracted from the other half of the sample. cDNAs were prepared and the
expression of IFNb and b-Actin monitored by RT-PCR. B. CHX blocks virus-induced degradation of IRF3 in human cells. Human MG63 or Namalwa cells
were treated as in A, total protein was prepared and analyzed for the expression of IRF3 and b-Actin. RNase protection assays (RPA) were conducted
to monitor the expression of IFNb and c-Actin mRNA (top panel). C. The proteosome inhibitor MG132 only partially inhibits the virus-induced
degradation of IRF3. MEFs were infected with SeV in the presence or absence of 1 mMo r5 0mM of MG132 for the indicated times, cells were
harvested for analysis of IRF3 and b-Actin protein expression or IFNb and b-Actin mRNA levels. D. The MAVS protein is cleaved and degraded in SeV
infected MEFs. MEFs were treated the same as in A, and the level of RIG-I, MAVS, and TBK1 proteins monitored using the appropriate antibodies. E.
Cleavage and degradation of MAVS revealed by another antibody. MEFs infected by SeV were lysed at different time points, and subjected to western
blot analysis with another anti-mouse MAVS antibody.
doi:10.1371/journal.pone.0020681.g001
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complete degradation of IRF3.
The PRDI-BF1 and PRDII-BF1 repressors are not required
for post-induction IFNb turn-off
Previous studies implicated two proteins, PRDI-BF1 and PRDII-
BF1 in the post-induction repression of IFNb expression [36,55].
The expression of both proteins is induced by virus infection, and
the kinetics of their induction is delayed compared to that of the
IFNb gene [36,55]. They both bind specifically to the IFNb
promoter, and both can function as repressors in vivo [56,57,58].
Transient over-expression of either repressor in cultured cells
potently inhibited IFNb reporter expression, strongly suggesting a
role in post-induction repression of IFN expression [36,55,59].
However, contrary to expectation, we found that reducing or
eliminating the expression of either PRDI-BFI or PRDII BF-1 had
little if any effect on the induction kinetics of the IFNb gene.
Specifically, knocking-down the expression of PRDI-BF1 in human
MG63 cells by siRNA (Fig. S2), or completely knocking-out either
PRDI-BF1 or PRDII-BF1 expression in MEFs did not alter the
kineticsofIFNbexpressioninresponsetovirusinfection(Fig.S3).In
addition, Knocking-down the expression of PRDII-BF1 in PRDI-
BF1knockout MEFsdid not affect the kinetics ofIFNb turn-off (Fig.
S4A–S4C). Thus, we conclude that neither PRDI-BF1 nor PRDII-
BF1 is required for the post-induction repression of IFNb
expression. Although we cannot exclude the possibility that yet to
be identified repressors play a role in IFNb turn-off, or that these
repressors function in other cell types, it appears that the
inactivation of the IRF3 protein alone is the mechanism for shutting
off IFNb gene expression during virus infection.
SeV-induced cleavage and degradation of MAVS in MEFs
We also explored the possibility that signaling components in
the IFNb induction pathway are degraded, preventing the
continuous activation of critical transcription factors, including
IRF3. Monitoring the expression of upstream signaling compo-
nents in MEFs during SeV infection revealed distinct expression
patterns for RIG-I, MAVS and TBK1 proteins (Fig. 1D). There
was little change in the level of TBK1 protein during infection. In
contrast, the RIG-I protein was strongly induced during the time
course of infection, as expected for an interferon inducible gene.
Strikingly, the level of the MAVS protein decreased over time, and
a 55KD band, likely a cleavage product of MAVS, appeared at a
later time point after viral infection (Fig. 1D). This was better
shown using a more sensitive MAVS antibody [60]: the level of full
length MAVS protein decreased between 7 and 14 hrs, and then
remained constant. Coincidentally, an induced 55KD band
appeared around 7 hrs, increased in intensity 14 hrs after infection
and then remained constant (Fig. 1E). Since the decreased level of
full length MAVS protein correlates with the appearance of the
new band, it is likely that this band is a cleavage product of
MAVS. Virus-induced degradation and cleavage of MAVS
protein was also observed in the murine Raw264.7 cell line (Fig.
S5A). Interestingly, CHX blocked SeV-induced MAVS cleavage
(Fig. 1D). Considering that IFN continues to be produced in the
presence of CHX, this observation shows that MAVS cleavage is
likely to be a post-induction event not required for the activation of
the IFNb gene. However, we investigated the function of virus-
induced MAVS cleavage. Experiments with MAVS deficient
MEFs reconstituted with a construct encoding mutant MAVS
protein that is not cleavable shows that the cleavage of MAVS is
not required for IFNb turn-off (Fig. S6). The same experiments
also showed that the cleavage of MAVS is not required for its
degradation (Fig. S6). Since CHX abolished post-induction IFNb
turn-off without elimination of MAVS degradation (Fig. 1A, 1D),
it is likely that the degradation of MAVS is dispensable for IFNb
turn-off. Nevertheless, the cleavage and degradation of MAVS
appears to provide another mechanism to prevent the continuous
activation of downstream factors.
We also note that the E3 ligase Itch, which has been reported to
be responsible for the SeV-induced MAVS degradation [27], does
not appear to be involved in the regulation of either the cleavage
or the degradation of MAVS in our hands (Fig. S5B).
Establishment of Sendai virus persistent infection in
cultured cells
In the course of studying SeV-induced IFNb expression kinetics,
we observed dramatically different fates of infected cells. Viral
infection of most cells leads to rapid cell death: almost 100% of the
cells die after 24 hrs infection with L929 and Raw264.7 cells; while
MG63 and Hela cells survive slightly longer but eventually die.
Interestingly, the growth of Namalwa cells and MEFs does not
appear to be affected by virus infection. To investigate this
phenomenon we attempted to maintain infected cells in culture,
and monitored the virus production and IFNb expression.
Remarkably, the virus load in Namalwa cells gradually decreased
with time, and IFNb gene expression also decreased (as mentioned
above, Namalwa cells have a slow IFNb turn-off rate). By day 19
post-infection, viral particles were difficult to detect. These
observations suggest that cultured Namalwa cells can eventually
clear the virus.
Monitoring infected MEFs revealed a different scenario: new
infectious virus particles were continuously generated and released
into the medium. This conclusion was supported by hemagglu-
tination inhibition assays with the culture medium (Fig. S7).
Surprisingly, IFNb expression was low despite abundant virus
present in these cells. An example is shown in Fig. 2B where MEFs
infected with SeV from 8 days to over one month, continued to
produce SeV nucleocapsid protein (NP) transcripts while the
expression of IFNb was extremely low. This is in contrast to the
robust and transient expression of the IFNb gene during the initial
24 hrs of infection (Fig. 2A). Cell death [61] during this extended
virus infection was not observed, and we have maintained these
cultures for over one year. SeV actively replicates in these cells
during the entire time course. Thus, we have established a SeV
persistent infection in MEFs; SeV and host cells coexist due to
equilibrium between viral replication and host cell metabolism. An
important feature of these cells is that the expression of the IFNb
gene is extremely low despite a high viral load. Based on this
unexpected finding, we initiated studies of the regulation of IFNb
expression in these persistently infected MEFs (PI-MEFs). All of
the PI-MEFs used in this study were cultured between 2–8 months
after the initial SeV infection.
We carried out additional assays to confirm the presence of virus
in the PI-MEFs. Immunofluorescent staining with an antibody
specific for SeV particles revealed that all of the cells were positive
for SeV in PI-MEFs, while no signal was detected in control MEFs
(Fig. 2C). However, we noticed that the number of virus particles
was highly variable between individual PI-MEFs. We also found
that total RNA extracted from PI-MEFswas as potent an inducer of
IFNb gene expression as the RNA extracted directly from SeV viral
stock when transfected into cells not previously exposed to infection
(Fig. S8). This observation suggests that SeV pathogen-associated
molecular patterns (PAMP) remain intact in PI-MEFs.
IFNb expression in PI-MEFs is inducible by CHX treatment
As an initial characterization of IFNb regulation in PI-MEFs,
we asked whether IFNb gene expression could be reactivated by
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recombinant IFNb protein, dsRNA (poly I:C), or the translation
inhibitor CHX (Fig. 2D). Not surprisingly, infection of PI-MEFs
with a new dose of SeV did not induce the expression of the IFNb
gene, considering that the cellular load of virus was already high.
Similarly, treating PI-MEFs with recombinant IFNb did not
induce the expression of the IFNb gene. dsRNA stimulation only
weakly activated the expression of IFNb in PI-MEFs, and the level
was much reduced compared to control MEFs (Fig. 2D). However,
a much larger stimulation of IFNb expression was observed when
the PI-MEFs were treated with CHX alone. By comparison, IFNb
expression was only weakly induced when control MEFs were
treated with CHX (Fig. 2D). Consistent with the finding that viral
particles are released from PI-MEFs, culture medium from these
cells strongly induced the expression of IFNb in control MEFs
(Fig. 2D). Taken together, these data show that SeV actively
replicates in PI-MEFs and strongly represses the expression of the
IFNb gene. The ability of PI-MEFs to produce IFNb is greatly
impaired when exposed to dsRNA. Strikingly, inhibiting protein
synthesis by CHX activates the expression of IFNb to a high level
in PI-MEFs. It therefore appears that PI-MEFs produce viral or
cellular proteins that block IFNb gene expression, and CHX
prevents the synthesis of these proteins. The response of PI-MEFs
to selective stimulators provides the opportunity to identify key
steps in the signaling pathway of IFNb activation that is blocked by
persistent infection.
The block of IFNb expression in PI-MEFs
As mentioned before, the signaling pathway leading to the
activation of IFNb expression by SeV infection is well established
[6]. To identify the step(s) at which the block to IFNb expression
occurs in PI-MEFs, we over-expressed individual signaling
components in the IFNb activation pathway in both control
MEFs and PI-MEFs. We then monitored the expression of the
endogenous IFNb gene in the absence or presence of a new SeV
infection. A similar transfection efficiency was observed in control
and PI-MEFs as indicated by comparable expression of GFP in
both cell types (Fig. S9), thus excluding the possibility that any
difference observed could be due to reduced transfection efficiency
in PI-MEFs.
As expected from previous studies [11,12,13,14], over-expres-
sion of the MAVS protein strongly induced the expression of
endogenous IFNb in control MEFs, even in the absence of viral
infection, and SeV-induced IFNb expression was enhanced in cells
in which MAVS was over-expressed (Fig. 3A). In contrast,
expression of the IFNb gene was only weakly induced in PI-
MEFs by MAVS over-expression. This weak induction did not
increase when a new dose of SeV infection was applied. The
inability of MAVS to induce IFNb expression in PI-MEFs was not
due to reduced levels of MAVS, since western blot analysis showed
similar if not higher levels of over-expressed MAVS in PI-MEFs
compared to control cells (Fig. S10). We conclude that the block to
IFNb production in PI-MEFs is downstream from the MAVS
protein in the IFNb induction signaling pathway. Similarly,
neither over-expression of RIG-I, or the IRF3/7 kinases TBK1 or
IKKe was sufficient to activate IFNb expression in PI-MEFs,
suggesting that the block to IFN production lies downstream of
these signaling components (Fig. 3A). By contrast, over-expression
of the transcription factors IRF3 or IRF7 strongly activated IFNb
expression, independent of new SeV infection in PI-MEFs
(Fig. 3A). By contrast, over-expression of the NFkB p65 subunit
only weakly reactivated IFNb expression in PI-MEFs, although it
boosted SeV-induced IFNb expression in control MEFs. Thus, it
appears that a primary block to IFNb expression in PI-MEFs is at
the level of IRF3/7 proteins. Consistent with this possibility, we
found that an IFNb promoter driven luciferase reporter gene was
strongly activated by IRF3 or IRF7 in PI-MEFs with or without
SeV infection (Fig. 3B). The basal level of luciferase activity was
very low in PI-MEFs in the absence of IRF3/7 transfection,
indicating that the expression of the IFNb reporter gene, like the
endogenous gene, is blocked in PI-MEFs.
Phosphorylation of specific serine residues in the C-terminus
IRF3 is required for IFNb gene activation [52,62]. To test whether
exogenously expressed IRF3 can bypass this requirement, expres-
sion constructs for mutant IRF3 proteins 5A or 7A (5A: S396, S398,
S402, S404 and S405 were all mutated to alanines, 7A has
additional S385 and S386 mutated to alanine) [53] were transfected
into PI-MEFs and induction of the endogenous IFNb gene
monitored. As expected, the 5A mutation only weakly activated,
Figure 2. Establishment of persistent SeV infection in MEFs. A.
The kinetics of IFNb expression and virus replication during acute SeV
infection. MEFs were infected with SeV and incubated for the indicated
times, total RNA was prepared, and the expression of IFNb, SeV NP and
b-Actin monitored by RT-PCR. B. SeV establishes a persistent infection
in MEFs. MEFs infected by SeV for 8 to 33 days were harvested, and total
RNA extracted. The expression of viral NP and the IFNb gene was
analyzed by RT-PCR. C. SeV is present in all PI-MEFs. Control MEFs or PI-
MEFs were fixed and subjected to immunofluorescent staining with an
anti-SeV antibody (green). Blue: DAPI staining for nuclei. Scale bar,
20 mm. D. Negative regulation of IFNb expression in PI-MEFs. Control
MEFs or PI-MEFs were subjected to a new dose of SeV infection, double
strand RNA (dsRNA, poly I:C) transfection or CHX (50 mg/ml) for 6 hrs,
control MEFs were also treated with culture medium from PI-MEFs for
6 hrs, and PI-MEFs were treated with recombinant IFNb protein
(1000 U/ml) for the same length of time, total RNAs were prepared
and the expression of IFNb, SeV NP and b-Actin were analyzed by RT-
PCR.
doi:10.1371/journal.pone.0020681.g002
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the IFNb gene in PI-MEFs (Fig. 3C). This experiment shows that
phosphorylation of IRF3 is also required for the activation of IFNb
expression in PI-MEFs; and upstream kinases responsible for IRF3/
7 phosphorylation can be activated (or already activated) in PI-
MEFs. Moreover, the exogenous, but not the endogenous IRF3, is
responsible for the activation of IFNb expression in these over-
expression assays. It is likely that endogenous IRF3 is inhibited in
PI-MEFs, and this inhibition could not simply be relieved by over-
expression of upstream components. However, this inhibition is
sensitive to CHX treatment.
IRF3 is negatively regulated in PI-MEFs
To further investigate the mechanism of IFNb repression in PI-
MEFs, we performed western blot analysis to monitor the
expression of various signaling molecules in PI-MEFs compared
to control MEFs. The abundant nucleocapsid protein (NP) from
PI-MEFs confirmed the high load of virus in these cells (Fig. 4A).
We found that the level of RIG-I protein in PI-MEFs returned to
pre-induction levels in MEFs. However, MAVS remained cleaved
and degraded in PI-MEFs as observed in control MEFs 24 hrs
post acute SeV infection (Fig. 4A). This observation suggests that
the mechanism responsible for MAVS cleavage and degradation is
constitutively active in PI-MEFs. In addition, IRF3 protein levels
were comparable or only slightly down in PI-MEFs compared to
that of control MEFs. Since we have established that the major
block to IFNb expression is at the level of IRF3/7 protein (Fig. 3A),
and IRF7 protein is too low to be detected in PI-MEFs, we focused
our attention on IRF3 regulation PI-MEFs.
Virus infection induces IRF3 protein phosphorylation, homo-
dimerization and nuclear translocation [63,64]. These events can
be visualized by immunofluorescent (IF) staining assays using an
Figure 3. The block to IFNb activation in PI-MEFs is at the level of IRF3/7. A. IRF3/7 transfection activates IFNb gene expression in PI-MEFs.
ControlMEFsorPI-MEFsweretransfectedwithplasmidsencodingRIG-I,MAVS,TBK1,IKKe,IRF3,IRF7 andp65 genes. 24 hrs later,cellswereinfectedwith
SeV for additional 6 hrs and RNA harvested for the analysis of IFNb and b-Actin expression by RT-PCR. B. IRF3/7 activates an IFNb gene reporter in PI-
MEFs. Control MEFs or PI-MEFs were transfectedwith the IFNb promoter firefly luciferase reporter gene togetherwith IRF3 or IRF7 expression constructs.
A renilla luciferase construct was also included for transfection reference. 24 hrs later, the cells were infected with SeV, and the luciferase activity
measured one day later. C. IRF3 mutations rendering the protein defective for phosphorylation failed to activate IFNb expression in PI-MEFs. PI-MEFs
were transfectedwith a Flag-taggedwild type IRF3expression construct or 5Aand7Amutants for30 hrs. RNAandprotein were harvested andanalyzed
for the expression of IFNb and b-Actin by RT-PCR, or probed with anti-Flag and MAP kinase p42/p44 antibodies by western blot analysis.
doi:10.1371/journal.pone.0020681.g003
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fraction of MEFs (,40%) displayed strong IRF3 signals in the
nucleus (Fig. 4B) and the number of cells in which this was the case
increased over time despite the decrease in the total level of IRF3.
At 24 hrs post-infection, IRF3 was observed in the nucleus of most
cells despite a significantly reduced level of expression (Fig. 4B,
and Fig. 1A). This observation, in conjunction with the time
course of IRF3 degradation indicates that virus-induced degrada-
tion of IRF3 likely occurs in the nucleus. Immunofluorescent
staining revealed that in contrast to the late time point of infection
in control MEFs, where IRF3 was observed in the nucleus of
greater than 95% cells, PI-MEFs display nuclear IRF3 signal in
only about 40% of the cells. This fraction did not increase when
the cells were subjected to a new SeV infection (Fig. 4B). The
reduced fraction of cells in which IRF3 is in the nucleus in PI-
MEFs compared to 24 hrs after initial infection suggests that some
of the nuclear IRF3 was either degraded or exported during the
establishment of persistent infection.
Notably, CHX treatment significantly increased the fraction of
PI-MEFs with nuclear IRF3 signal to about 90% (Fig. 4B), and
also increased the level of IRF3 dimers detected by native gel
analysis (Fig. 4C). It is important to note that low levels of IRF3
dimers are constitutively present in PI-MEFs. CHX also induced
the nuclear translocation of IRF3 in control MEFs (observed in
.90% cells, Fig. 4B), but only weakly induced the expression of
the IFNb gene (Fig. 1A and 2D). In addition, the nuclear IRF3 in
CHX treated MEFs was not detected as a dimer by native gel
electrophoresis (Fig. 4C). It is therefore possible that the activation
of IFNb gene expression by CHX in PI-MEFs is primarily through
the relief of the nuclear inhibition of IRF3 in these cells. However,
it is also likely that the IRF3 protein activated by CHX acquired
the ability to activate the IFNb gene in the presence of SeV in PI-
MEFs.
Taken together, these data suggest that in PI-MEFs there is
cytoplasmic inhibition that prevents IRF3 activation (IRF3
remained in the cytoplasm, observed in ,50–60% of the cells),
and nuclear inhibition that suppress the transcriptional activity of
IRF3 (observed in the remaining cells, with IRF3 stayed in the
nucleus). The strong IFNb induction by CHX is likely due to the
relief of inhibition in both the nucleus and cytoplasm.
Antiviral drug treatment activates IFNb expression in PI-
MEFs
The inhibition of IFNb gene expression in PI-MEFs is similar to
that observed with persistent viral infections where the expression
of IFN genes is suppressed [45]. Thus, PI-MEFs could serve as a
model system to test the effects of anti-viral drugs. While we found
that treating these cells with MG132 did not induce the expression
of IFNb, we found ribavirin, an anti-RNA virus drug [65],
induced the expression of the IFNb gene in PI-MEFs. As shown in
Fig. 5A, ribavirin treatment of PI-MEFs induced the expression of
IFNb, IRF7 and STAT1, in contrast to the weak induction of
IRF7 and STAT1 but not IFNb in control MEFs (Fig. 5A). We
note from immunofluorescent staining experiments that the
activation of the IFNb gene by ribavirin in PI-MEFs is not due
to increased IRF3 nuclear localization. Sustained treatment of PI-
MEFs with ribavirin significantly reduced the virus load in these
cells, and partially restored the induction of IFNb by a new dose of
virus infection (Fig. S11).
Figure 4. Regulation of IFNb activation pathway signaling molecules in PI-MEFs. A. Expression of RIG-I, MAVS , IRF3, SeV NP and b-Actin in
PI-MEFs. Control MEFs infected with SeV for the indicated times and PI-MEFs before and after CHX treatment were harvested; whole cell lysates were
prepared and separated by SDS-PAGE, and western blots probed with antibodies specific for the indicated proteins. B. Subcellular localization of IRF3
in control MEFs and PI-MEFs infected with SeV, or treated with CHX. Cells were subjected to various treatments for indicated time, and fixed for IRF3
staining. The percentage of cells (out of ,150 cells) with nuclear IRF3 staining under different conditions was determined and shown below the
images. Data represent at least three independent experiments. Scale bar,10 mm. C. IRF3 dimerization in virus infected MEFs and CHX treated PI-
MEFs. Control MEFs were infected with SeV, PI-MEFs were treated with CHX for indicated time. Total cell lysates were prepared and subjected to
native gel electrophoresis and probed with IRF3 antibodies. TBK1 knockout MEFs were also infected with SeV in parallel for a negative control.
doi:10.1371/journal.pone.0020681.g004
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20681Figure 5. Interferon signaling is defective in PI-MEFs. A. ISGs are not activated by recombinant IFNb in PI-MEFs, but ribavirin treatment
activated the expression of ISGs and IFNb. Control MEFs and PI-MEFs were treated with recombinant IFNb (1000 U/ml) or ribavirin (100 mg/ml) either
alone or in combination for 11 and 24 hrs. Cells were harvested for total RNA extraction, and the expression of IFNb, Stat1, IRF7 and b-Actin mRNAs
were analyzed by RT-PCR. B. ISGF3 complex formation is blocked in PI-MEFs. Control MEFs and PI-MEFs were stimulated with recombinant IFNb
protein for 1 hr, and total cell extracts prepared and assayed for the ISGF3 formation on ISRE DNA probes derived from the ADAR1 and MX1 genes. C.
Reduced phosphorylation of STAT1 tyrosine 701 in PI-MEFs after IFN treatment. Top: Control MEFs and PI-MEFs were transfected with a plasmid
encoding Stat1a protein for 24 hrs, transfected and non-transfected cells were stimulated with recombinant IFNb for 1 hr. Total protein was prepared
for western blot analysis with antibodies against Stat1, phospho-tyrosine 701 Stat1, Stat1a and MAP kinase p42/p44. Bottom: the same experiments
were conducted in IFNAR1 deficient MEFs and the expression of Stat1 and phospho-Y701 Stat1 were analyzed by western blotting. GFP was also
transfected as a control. D. Plasma membrane localization of Stat1 protein in PI-MEFs. Control MEFs and PI-MEFs were transfected with a plasmid
encoding Flag-tagged Stat1 protein. 24 hrs later cells were fixed and subjected to immunofluorescent staining with an anti-Flag antibody (green).
Blue: DAPI staining for nuclei. Scale bar, 10 mm. E. SeV C protein specifically interacts with Stat1 protein. Constructs for Flag-tagged SeV C, V, P and NP
proteins were transfected into MEFs, 24 hrs later, whole cell extracts were prepared and subjected to anti-Flag M2 bead immunoprecipitation (IP).
The associated proteins were eluted and separated on SDS-PAGE, blotted and probed with an anti-Stat1 antibody. An hnrnp U expression construct
was also included as a control. IB: immunoblot.
doi:10.1371/journal.pone.0020681.g005
Negative Regulation of IFN Gene Expression
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e20681Since ribavirin and IFN are frequently used in combination to
treat chronic HCV infections [65], we also tested whether
recombinant IFNb can enhance the induction of the IFNb gene
by ribavirin in PI-MEFs. The effects were found to be minimal
(Fig. 5A). Surprisingly, treating PI-MEFs with recombinant IFNb
failed to induce the expression of IRF7 and STAT1, although they
were strongly induced by IFNb in control MEFs (Fig. 5A). Thus, it
appears that not only is the IFNb activation pathway blocked in
PI-MEFs, but the IFN signaling pathway is blocked as well.
Interferon signaling is blocked in PI-MEFs
The observation that recombinant IFNb did not induce IRF7
and STAT1 expression in PI-MEFs suggests that IFN signaling is
blocked in these cells. To test this possibility, we examined the
hallmark of IFN signaling: formation of the ISGF3 complex and
phosphorylation of STAT1 upon IFN stimulation [66]. In control
cells, IFN treatment induced the formation of the ISGF3 complex
on an ADAR1 promoter probe, while this complex was virtually
absent in PI-MEFs treated with IFN (Fig. 5B). Although the
binding was weaker, the MX1 promoter probe revealed the same
pattern (Fig. 5B). These observations show that PI-MEFs are
defective in the induction of ISGF3 complex formation by IFN.
The failure to detect inducible ISGF3 binding could be due to
either reduced expression of the ISGF3 components (STAT1,
STAT2 and IRF9), reduced accessibility of STAT protein to
JAK/TYK kinase, or reduced kinase activity in these cells. We
therefore carried out a western blot analysis and probed the blot
for total and tyrosine (Y) 701 phosphorylated STAT1. The basal
level of STAT1 protein in PI-MEFs was 2–3 fold lower than that
in control MEFs (Fig. 5C). In addition, the phospho-Y701 STAT1
level was much lower (.5 fold) than that in IFN-stimulated control
cells (Fig. 5C). Thus, in addition to the reduced levels of STAT1
protein in PI-MEFs, it appears that the Jak/STAT pathway is also
inhibited, accounting for the reduced Y701 phosphorylation.
We asked whether the kinases responsible for Y701 phosphor-
ylation were impaired in PI-MEFs. To compensate for the reduced
level of STAT1 in PI-MEFs, we exogenously expressed Flag-
tagged STAT1a protein in control MEFs and PI-MEFs, and
monitored its Y701 phosphorylation after IFN stimulation.
Unexpectedly, STAT1 over-expression was sufficient to induce
similar levels of Y701 phosphorylation of the exogenous STAT1 in
both control MEFs and PI-MEFs (it also induced Y701
phosphorylation of the endogenous STAT1 protein in control
MEFs, Fig. 5C, top panel). IFN stimulation only weakly increased
the Y701 phosphorylation level in both control MEFs and PI-
MEFs. Since STAT1 over-expression did not induce IFNb
expression in PI-MEFs (Fig. S12), the Y701 phosphorylation
observed in these cells suggests that STAT1 can be phosphorylated
independent of IFN signaling. This was indeed confirmed by
experiments with IFN receptor deficient (IFNAR1 2/2) MEFs,
where over-expression of STAT1 induced Y701 phosphorylation
(Fig. 5C, bottom panel). Taken together, these data suggest that
kinase activity appears to be intact in PI-MEFs, but the reduced
expression of STAT1 and other mechanisms resulted in reduced
phosphorylation after IFN stimulation.
To explore additional mechanisms regulating STAT1 in PI-
MEFs, we monitored its intracellular distribution by transfecting
Flag-tagged STAT1 into cells followed by immunofluorescent
staining of the Flag peptide. In transfected control MEFs, the
cytoplasmic STAT1 was evenly distributed (Fig. 5D). However, in
PI-MEFs STAT1 was highly enriched in plasma membrane
fractions (observed in ,35% cells) (Fig. 5D). The aberrant
localization of STAT1 protein in PI-MEFs is likely to also
contribute to the defects of IFN signaling in these cells.
The SeV C protein has been reported to specifically interact
with STAT1, and lead to its degradation [67,68]. Recently it was
also shown that the C protein can localize to the plasma
membrane [69]. Consistent with these observations, we were able
to use Flag-tagged C protein to pull down endogenous STAT1
from MEFs (Fig. 5E). Therefore, it is likely that the block to IFN
signaling and the aberrant localization of STAT1 are caused, at
least in part, by the viral C protein in PI-MEFs.
Viral genes required for the establishment of persistent
infection
Both the translation inhibitor CHX and the antiviral drug
ribavirin activated IFNb gene expression in PI-MEFs, suggesting
that viral protein(s) might be directly involved in the repression of
IFNb expression. As a member of the paramyxovirus family, SeV
encodes 6 major open reading frames (ORFs), corresponding to
nucleocapsid (NP), phosphorylation (P), matrix protein (M), fusion
protein (F), hemagglutinin neuraminidase (HN) and large (L)
protein along the sense strand of its RNA genome. The
phosphorylation (P) ORF can also give rise to a small protein C
(mentioned above, with a different starting site and a different
frame of ORF) and another protein V (shares a common N-
terminus with the P protein, but has a unique cysteine rich C-
terminus) [46]. We generated expression constructs bearing
cDNAs encoding each of these proteins, and tested whether any
of them inhibit the induction of IFNb by various inducers.
Luciferase reporter assays showed that four out of the eight
proteins tested, NP, C, V and P, strongly inhibited the induction of
the IFNb reporter when SeV was used as the inducer (Fig. 6A). V
and P proteins also significantly attenuated IFNb induction by
dsRNA in reporter assays (Fig. 6B). To identify the specific
signaling components affected by these proteins, we conducted
luciferase reporter assays with over-expression of MAVS, TBK1,
IRF3 and IRF7 proteins. Although each viral protein showed
considerable inhibition of IFNb induction when MAVS was over-
expressed, the inhibition by V protein was the strongest (Fig. 6C).
Significant inhibition of the IFNb reporter by the V protein was
also observed with TBK1 over-expression (Fig. 6C). Unexpectedly,
instead of the inhibition seen in MAVS induction, NP expression
stimulated IFNb induction by TBK1 (Fig. 6C). We note that the V
protein is the only viral protein tested, that decreases the induction
of the IFNb reporter when co-expressed with IRF3 or IRF7
(Fig. 6D).
To determine whether the V protein can interact with IRF3, we
transfected 293T cells with Flag-tagged NP, C, V and P proteins
together with HA tagged IRF3 protein. Viral proteins were
immunoprecipitated using anti-Flag beads, and separated by SDS-
PAGE. A Western blot using anti-HA antibodies as a probe
revealed that the V protein strongly interacts with IRF3 (Fig. 6E).
The same experiment showed that the C protein also interacts
with IRF3, although it did not inhibit the transactivation activity of
IRF3 in the IFNb reporter assays (Fig. 6D, 6E).
We also examined the localization of these viral proteins in
MEFs by expressing GFP fusion constructs. Consistent with a
previous report [69], we observed that C protein localized to the
plasma membrane, but was also detected in the cytoplasm and
nucleus (Fig. 6F). The V protein is detected in both the cytoplasm
and nucleus in both control and PI-MEFs (Fig. 6F). Since the life
cycle of SeV is exclusively in the cytoplasm (structural components
of SeV are all made in the cytoplasm), the detection of C and V
proteins in the nucleus highlights their functions in antagonizing
IFN activation and signaling. Strikingly, while the NP and P
proteins were distributed evenly in the cytoplasm in control MEFs,
signals of these two proteins displayed aggregated patterns in PI-
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PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e20681Figure 6. SeV encoded proteins inhibit IFNb expression. A. NP, C, V and P proteins inhibit IFNb reporter induction by SeV. Expression
constructs for SeV proteins were cotransfected into 293T cells with an IFNb promoter driving firefly luciferase expression plasmid together with a
renilla luciferase reporter. 24 hrs later the cells were infected with SeV and luciferase activities measured after an additional 24 hrs.The PRDI-BF1
expression construct was also transfected as a control. B. SeV C, V and P proteins suppress IFNb induction by dsRNA (poly I:C). Experiments were
conducted as in A, but dsRNA (2 mg/ml) was used instead of SeV to induce IFNb expression. C. MAVS and TBK1 induced IFNb expression is strongly
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the sites of virus assembly in PI-MEFs.
shRNA targeting SeV PVC gene dramatically changes
SeV-induced cellular innate immune response
To directly test the effects of inhibiting SeV replication on IFNb
expression in PI-MEFs, we knocked-down the expression of the
SeV encoded genes by shRNA. However the knockdown
efficiency was not satisfactory probably due to the high
abundances of the viral loads in these cells. We thus treated
MEFs with shRNA specifically targeting SeV PVC gene and then
infected with SeV for increasing times. Western blot analyses
revealed that the production of SeV C, V and P proteins was
abolished by this shRNA treatment, and the increasing amounts of
the NP protein overtime in the infected control cells treated with a
scramble shRNA was not observed (Fig. 7A). Notably, the
degradation of IRF3 was similarly observed in both cells
(Fig. 7A), correlating the similar IFNb turn-off kinetics in cells
treated with both shRNAs (Fig. 7B). This observation suggests that
the degradation of IRF3 is most likely the result of host cell
proteins. Strikingly, the induction of STAT1 was dramatically
enhanced in cells treated with PVC shRNA, and the cleavage and
degradation of MAVS was also reduced in these cells. These data
clearly show that SeV encoded proteins are indeed capable of




Here we show that inactivation of the transcription factor IRF3
plays a critical role in the negative regulation of IFNb expression
during both acute and persistent Sendai virus infections. Western
blot analyses reveal that the level of IRF3 correlates with IFNb
gene expression during acute virus infection. The degradation of
IRF3 leads to the termination of IFNb transcription, and
stabilization of IRF3 with CHX sustains IFNb gene transcription.
Turnover of IRF3 would prevent enhanceosome assembly [70],
and thereby turn-off IFNb expression. Activation of IFNb gene
expression requires IRF3, IRF7 and NFkB [70], but we find that
the levels of IRF7 and p65 remain relatively constant during the
course of viral infection (Fig. 1A). This observation correlates with
the essential role of IRF3 in the activation of the IFNb gene, as
deletion of IRF3 in mice leads to a dramatic reduction in the level
of IFNb expression after virus infection [71]. IRF7 is required for
high levels of IFN gene expression [72], but it is present at only low
levels prior to virus infection [72]. Moreover, the super induction
of IFNb by CHX treatment of virus infected cells [37], which leads
to high levels of IFNb mRNA, occurs in the absence of IRF7
induction. Thus, it appears that IRF3 plays a unique and essential
role in IFNb induction.
While we were able to confirm previous studies showing that
proteosome inhibition by MG132 treatment stabilizes IRF3
[52,53], we show that the proteosome is not the sole mechanism
for IRF3 degradation. Specifically, we find that significant IRF3
degradation can be observed in virus infected cells treated with
MG132 for 24 hrs. In fact, CHX appears to be a more efficient
inhibitor of the virus-induced degradation of IRF3. While it is
possible that CHX treatment prevents the synthesis of an inducible
E3 ligase that targets IRF3 for degradation, we propose that one
or more proteosome-independent proteases that target IRF3 are
induced by virus, leading to the termination of IFNb transcription
Figure 7. Interfering SeV replication with shRNA affects innate
immune response. A. Targeting SeV by shRNA modulates the
expression of critical factors in innate immunity. MEFs were treated
with shRNA specifically targeting the SeV PVC gene or a scramble
sequence shRNA as control. Cells were then infected with SeV. Total
protein lysates were prepared after indicated time and separated on
SDS-PAGE for western blot analyses with anti-STAT1, MAVS, IRF3, SeV C,
V, P and NP and b-Actin antibodies. B. Targeting SeV by shRNA has
minimal effects on IFNb expression kinetics. Experiments were
conducted similarly as in A, but cells were harvested after indicated
time for RNA extraction instead. The expression of IFNb, Cxcl10, SeV NP
and b-Actin was analyzed by RT-PCR.
doi:10.1371/journal.pone.0020681.g007
suppressed by the SeV V protein. The IFNb promoter driving firefly luciferase reporter was transfected with a reference renilla construct together with
MAVS or TBK1 expression constructs. SeV NP, C, V and P protein expression constructs were also included separately, luciferase activities were
measured 24 hrs later. D. The V protein of SeV inhibits IFNb induction by the over-expression of IRF3 or IRF7 protein. Experiments were conducted as
in C, but IRF3 and IRF7 expression constructs were cotransfected instead of MAVS or TBK1, luciferase activities were measured 24 hrs later. E.
Interactions between SeV protein and IRF3. Plasmids encoding Flag-tagged SeV NP, C, V and P proteins were cotransfected with plasmid encoding
HA-tagged IRF3, total cell lysates were prepared 24 hrs later and subjected to immunoprecipitation with anti-Flag beads. The associated proteins
were separated in SDS-PAGE and blot with anti-HA or anti-Flag antibodies. F. Distinct localization of SeV NP, C, V and P proteins. GFP-fusion
constructs for NP, C, V and P proteins of SeV were generated and transfected into control MEFs and PI-MEFs. 24 hrs after transfection, cells were fixed
and directly analyzed with confocal microscopy. Blue: DAPI staining for nuclei. Scale bar, 10 mm.
doi:10.1371/journal.pone.0020681.g006
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in Fig. S13).
Induced IRF3 degradation was previously observed with other
virus infections. For example, the paramyxovirus family Newcastle
disease virus and Measles virus induce IRF3 degradation in
various cell lines [73,74]. Moreover, vesicular stomatitis virus also
induces IRF3 degradation in A549 cells [75], and dsRNA (poly
I:C) induces strong turnover of IRF3 in MEFs [53,75]. Additional
studies will be required to determine whether the loss of IRF3 in
these cases correlates with the kinetics of IFNb down regulation.
Assuming that this is the case, IRF3 degradation may serve as a
general mechanism for turning off IFNb gene expression.
We also present evidence that the two repressor proteins PRDI-
BF1 and PRDII-BF1, which bind specifically to the IFNb
enhancer, and were thought to be involved in post-induction
IFNb repression [36,55], do not appear to be required in knock-
out mouse cells. We find that MEFs deficient for either PRDI-BF1
or PRDII-BF1 display the same kinetics of IFNb turn-off as wild
type cells after virus infection (Fig. S3). The possibility that the two
repressors are redundant was ruled out by the observation that
shRNA knockdown of PRDII-BF1 in PRDI-BF1 knockout MEFs
display normal kinetics of IFNb down regulation after virus
infection (Fig. S4C). Although we cannot rule out the possibility
that one or both of these proteins function as post-induction
repressors of IFNb gene expression in other cells, it would appear
that IRF3 turnover is the primary mechanism of post-induction
repression.
Negative regulation of the IFNb gene in persistent
infected cells
We have shown that SeV infection of MEFs can lead to a
persistent infection in which IFNb gene expression is repressed
and viral replication continues. As is the case in vivo, where
different tissues display varying susceptibilities to virus infection
[76], we find that the ability to establish persistent infection
depends on the cell type. For example, we show that SeV kills
L929, Raw264.7, MG63 and Hela cells, while the virus is cleared
from Namalwa cells. In the case of MEFs, viral replication must
establish equilibrium with cellular metabolism, leading to long-
term cell survival. An important feature of persistently infected
MEFs is that IFNb production is strongly repressed even though
the virus continues active replication. Examination of the
expression of signaling components in PI-MEFs, and of late time
points during acute SeV infections revealed that the MAVS
protein is cleaved and degraded in both cases. We have mapped
the cleavage sites on MAVS (Fig. S6), but the mechanism and
function of MAVS cleavage and degradation remain to be
investigated.
We have identified two non-redundant inhibitory mechanisms
that operate in PI-MEFs to prevent IFNb activation. One acts in
the cytoplasm to inhibit the activation of IRF3 and its nuclear
translocation. The second acts in the nucleus, to prevent IFNb
gene activation by the nuclear IRF3 protein. We show that IRF3 is
activated and migrates to the nucleus in a significant fraction
(,40%) of PI-MEFs (Fig. 4B), indicating that the upstream
signaling pathway is functioning. This observation also suggests
that the cleavage and degradation of MAVS might be a byproduct
of signal activation, rather than a critical step (i.e. termination of
the activated signaling cascade). The transcriptional activity of
nuclear IRF3 in PI-MEFs appears to be blocked, and this block
can be overcome by expressing exogenous IRF3 or IRF7 (Fig. 3A).
We speculate that the excess IRF3 or IRF7 in these experiments
blocks the negative factors by competitive inhibition. CHX or
ribavirin treatment also activates endogenous IFNb expression in
PI-MEFs (Fig. 2D, 5A), suggesting that viral proteins are directly
involved in these inhibitory mechanisms.
We find that the SeV NP, C, V and P proteins can all inhibit the
induction of IFNb by SeV (Fig. 6A). It is possible that NP and P
proteins interfere with the detection of the viral RNA by cellular
sensors, as both proteins associate with the viral RNA genome as
structural or polymerase components [46]. Notably, the nucleo-
proteins from many Arenaviruses can also inhibit type I IFN
expression [77,78], it is likely they also interfere with the virus
detection step.
In contrast to some V proteins from Rubulavirus, which inhibit
IRF3 activation by competing with the TBK1/IKKe kinases [79],
we find that the V protein from SeV directly inhibits the activity of
IRF3, thus providing a clear mechanism for the suppression of
IFNb expression in PI-MEFs. This is consistent with a previous
observation that SeV V protein inhibits IFNb activation [80]. In
addition to published results that SeV V protein can specifically
inhibit the activity of the RNA sensor MDA-5 [81,82], we found
that the V protein potently inhibits the induction of an IFNb
reporter by virus, dsRNA and over-expression of MAVS or TBK1
(Fig. 6A–C). Importantly, the V protein is the only viral protein
capable of inhibiting IFNb induction by IRF3/7 over-expression
in reporter assays (Fig. 6D). The physical interaction between the
V protein and IRF3 was demonstrated by co-immunoprecipitation
experiments (Fig. 6E). The V protein is found in both the
cytoplasm and nucleus (Fig. 6F); and therefore, has the potential to
inhibit IRF3 activity in both compartments. The finding that the
V protein specifically targets IRF3 is also supported by an in vivo
study, where recombinant SeV devoid of the V protein was rapidly
cleared from infected mice, except ones deficient for IRF3 gene
[83]. We propose that the inhibition of IRF3 by the V protein is
the primary mechanism for the repression of IFNb expression in
persistently infected cells (Fig. S13).
The mechanism by which the C protein inhibits IFNb induction
is less clear. The C protein can also interact with IRF3 in over-
expression experiments, but the inhibition appears to occur
upstream of IRF3/7. The C protein inhibited the induction of
the IFNb reporter by both MAVS and TBK1, but not IRF3/7
(Fig. 6D). In previous studies the C protein was shown to
antagonize IFN signaling by specifically interacting with STAT1
and interfering with its activity (Fig. 5E, [67]). Similarly, the C
protein is also essential for the in vivo pathogenicity of SeV [84].
Thus, in our PI-MEFs, SeV suppresses the activation of the IFNb
gene, and also inhibits IFN signaling by targeting the key
transcription factors IRF3 and STAT1. Both of these activities
are required for persistent infection by SeV, as recombinant virus
devoid of either C or V proteins is rapidly cleared from infected
mice [83,84]. However, the question of whether this is a general
strategy used by other viruses to establish persistent infection
remains to be answered.
Materials and Methods
Cells, chemicals, reagents and plasmids
Immortalized wild type MEFs were from Wen-chai Yeh
(Toronto, Canada), 293T, Hela, MG63, Namalwa, L929,
Raw264.7 cells are all from ATCC. Cycloheximide is from
calbiochem, ribavirin, recombinant interferon-b and MG132 are
from Sigma. Expression constructs for MAVS, TBK1, IRF3, IRF7
and Stat1a were described before [53,85,86,87]. Flag-tagged
expression constructs for SeV NP, C, V and P proteins were
generated by cloning viral cDNAs to pcDNA3-Flag (Invitrogen) or
pFlag-CMV2 (Sigma) vectors. GFP-fusion constructs for these
proteins were generated by Gateway cloning with pcDNA-
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Charles River laboratory. For viral infections, SeV was added
directly into the medium at a concentration of 200–300 HAU/ml
and incubated for indicated time. Procedures for lentivirus-
mediated shRNA knockdown experiments were described before
[86], sequences 59-GAAGACCAAGCTGAAGGACTT-39 and 59-
CGCTCAGAGGTGCAAGCTTAA-39 were cloned to pLKO.1
vector to target SeV PVC and mouse Itch gene respectively.
Luciferase assays
293T Cells or MEFs were transfected with IFNb promoter
driving firefly luciferase construct together with renilla luciferase
construct as reference. Cells were either directly treated with SeV
or double strand RNA (poly I:C), or co-transfected with other
expression constructs. 24 hrs later cells were lysed and subjected to
Dual-Glo luciferase assay analysis (Promega) with an Analyst AD
plate reader.
Antibodies, western blot and immunoprecipitation
Antibodies against RIG-I, rodent specific MAVS, TBK1, IKBa,
MAP kinase p42/p44 are from Cell Signaling, anti-mouse IRF3,
IRF7 antibodies are from Invitrogen. Anti-p65, human IRF3,
Stat1, Stat1a antibodies are from Santa Cruz. b-actin, phosphor-
Y701 Stat1 antibodies are from Abcam. Anti-Flag antibody and
agarose beads are from Sigma. Anti-mouse MAVS antibody is a
gift from Dr. James Chen (UT southwestern, Dallas TX). Anti-
SeV antibody used for cell staining is a gift from Dr. Ben tenOever
(Mount Sinai, New York). Anti-SeV NP serum is from Dr. Valery
Grdzelishvili (Charlotte, USA). Anti-SeV C protein antibody is
from Dr. Ganes Sen (Cleveland, USA). Anti-SeV P and V serum is
from Dr. Atsushi Kato (National Institute of Infectious Diseases,
Japan). Western blots were carried out according to standard
protocols. About 50 mg of total protein lysate (lysed in a buffer of
20 mM Tris-HCl, pH7.5, 150 mM NaCl, 1% Triton X-100,
1 mM EDTA, 30 mM NaF, 1 mM glycerolphosphate, 16
proteinase inhibitor (Roche) and 1 mM Na3VO4) was denatured
in sampling buffer (50 mM Tris-HCl, pH 6.8, 10% glycerol, 2%
SDS, 0.02% bromophenol blue and 2.5% b-mecaptoethanol) and
subjected to SDS-PAGE. Proteins were transferred to a PVDF
membrane, blocked with 5% milk in Tris-buffered saline Tween
20 (TBST), and incubated with various primary antibodies
solutions. Washed membranes were incubated with HRP
conjugated secondary antibody and protein bands visualized with
ECL reagents (Millipore or Pierce). Immunoprecipitation exper-
iments were carried out by incubating anti-Flag M2 beads with
about 500 mg of total protein lysates (prepared with the lysis buffer
described above) for 2 hrs at 4uC, beads were collected and
washed 4 times with the same buffer. Bound proteins were eluted
in sampling buffer and subjected to western blot analysis.
RNase protection assays, RT-PCR
RNase protection assays were conducted as described before
[37], anti-sense probe for human IFNb and gamma-actin were
generated by in vitro transcription and gel purified. About 30 mgo f
total RNA were hybridized with probes over night at 50uCi na
buffer (40 mM PIPEs, pH 6.8, 1 mM EDTA,0.4 M NaCl and
80% formamide) and RNAs not annealed were digested with
RNase A/T1 mixture (Ambion). Samples were then denatured
and separated in a denaturing gel. Dried gel was exposed to
Phosphoimager. RT-PCR was conducted according to routine
protocols, cDNAs were made from about 5 mg of total RNA by
oligo-dT primer with AMV reverse transcriptase (Promega). Gene
specific primers (Table S1) were used to amplify the desired
products.
Immunofluorescent staining
Immunofluoresence staining was conducted according to
standard procedures. Cells were fixed with 4% formaldehyde in
PBS for 10 min, and washed for 3 times, 5 min each. Cells were
permeabilized with 0.1% Triton X-100 in PBS for 10 min, then
washed again three times 5 min each. Primary antibody
incubation was carried at 4uC over night. Cells were extensively
washed, and incubated with FITC-conjugated 2
nd antibody. Slides
were mounted and subjected to microscopy analysis. In the case of
GFP fusion viral protein, transfected cells were fixed, washed and
directly mounted before microscopy analysis.
Electrophoresis mobility shift assays
About 10 mg of total cell lysates were incubated with 25 ng of
radio-labeled ADAR1 or MX1 probe at 37uC for 20 min in a
buffer of 12 mM Tris-HCl, pH8.0, 60 mM KCl, 2 mM MgCl2,
0.12 mM EDTA, 0.3 mM DTT and 6% glycerol, and resolved in
a 5% native PAGE gel. Dried gels were exposed to Phosphoima-
ger.
Supporting Information
Figure S1 Effects of proteosome inhibitors on virus-
induced IRF3 degradation. A. MG132 potently blocks TNFa
induced IKBa degradation. MEFs were treated with recombinant
TNFa (10 ng/ml) for 20 min in the presence or absence of
MG132 (50 mM). Total protein lysates were prepared and
subjected to western blot analysis for the detection of IKBa and
b-Actin. B. Lactacystin does not completely block SeV-induced
IRF3 degradation. MEFs were infected with SeV in the presence
or absence of lactacystin (10 mM, a concentration known to
potently inhibit proteosome activities [53,88]) for 6 and 24 hrs.
Total protein lysates were prepared and subjected to western blot
analysis for the detection of IRF3 and b-Actin.
(EPS)
Figure S2 Knocking down the expression of PRDI-BF1
in MG63 cells did not sustain IFNb expression. MG63 cells
were transfected with siRNAs targeting PRDI-BF1 gene. 36 hrs
after transfection, cells were infected with SeV for 8 hrs and
24 hrs, total RNA extracted for the analysis of IFNb and GAPDH
expression (top panel). The efficiency of knocking-down was
monitored by western blot (bottom panel).
(EPS)
Figure S3 Neither PRDI-BF1 nor PRDII-BF1 is required
for IFNb turn-off in MEFs. A. PRDI-BF1 is not required for
IFNb turn-off after SeV infection. The diagram of PRDI-BF1
locus and the genotyping results of PRDI-BF1 deficient MEFs and
control wild type cells are shown in the top panel, exons 6–8 are
targeted for the deletion in the knockout cells. The kinetics of
IFNb expression in wild type and PRDI-BF1 deficient cells after
SeV infection monitored by RT-PCR is shown in the bottom
panel. B. PRDII-BF1 is not required for IFNb turn-off. The
PRDII-BF1 gene locus, genotyping results and IFNb expression
kinetics are shown the same as in A. The entire exon 3 (5939 bp)
of PRFII-BF1 gene is deleted in the deficient cells.
(EPS)
Figure S4 Knocking-down PRDII-BF1 expression in
PRDI-BF1 knockout MEFs does not affect IFNb turn-
off. A. Genotyping results of wild type MEF and PRDI-BF1
knockout MEFs treated with shRNA targeting PRDII-BF1 or a
control scramble shRNA. Primer pair a in Fig. S3A was used for
PRDI-BF1 detection, and ATP1a1 gene was amplified as a
control. B. shRNA knockdown efficiency of PRDII-BF1. Scramble
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left uninfected, or infected with SeV for 4 hrs, and total cellular
RNA extracted for RT-PCR analysis of PRDII-BF1 and b-Actin
expression. C. Normal post-induction turn-off of IFNb in PRDI-
BF1 knockout MEFs with reduced PRDII-BF1 expression.
Scramble or PRDII-BF1 shRNA treated PRDI-BF1 knockout
MEFs were infected with SeV for indicated time, cells were
harvested and RNA extracted for the analysis of IFNb and b-Actin
expression by RT-PCR.
(EPS)
Figure S5 Itch is not involved in the regulation of MAVS
cleavage or degradation. A. SeV induces degradation and
cleavage of MAVS protein in Raw264.7 cells. Raw264.7 cells were
infected with SeV for the indicated times, total protein lysates were
prepared and analyzed for the expression of the MAVS protein by
western blot. B. Knocking-down the expression of Itch does not
affect SeV-induced MAVS cleavage and degradation. Wild type
MEFs were treated with shRNA targeting Itch or a control
scramble shRNA, and subjected to SeV infection. Total protein
lysates were prepared after indicated time and subject to western
blot for the expression of MAVS, Itch and b-Actin.
(EPS)
Figure S6 Cleavage of MAVS is not required for IFNb
turn-off. MAVS deficient MEFs were reconstituted (RC) with
wild type or I441A mutant MAVS proteins, and subjected to SeV
infection. Half of the samples were harvested for RT-PCR analysis
of IFNb and b-Actin expression (bottom panel), and the other half
were analyzed by western blot for the cleavage and degradation of
the MAVS protein (top panel).
(EPS)
Figure S7 Culture medium of PI-MEFs contains virus
particles. Hemagglutination inhibition assays were conducted to
confirm the release of virus particles into the culture medium of
PI-MEFs. Series dilutions of culture medium from control MEFs
or PI-MEFs (2 months after initial infection) or SeV stock were
added to wells containing chicken red blood cells. Presence of virus
inhibited the agglutination of these cells.
(EPS)
Figure S8 Total RNA extracted from PI-MEFs is a
potent IFNb inducer. Total RNA extracted from control
MEFs, PI-MEFs or Sendai virus stock were transfected into
control MEFs (8 mg of total RNA from control MEFs and PI-
MEFs, and about 1 mg of SeV RNA were transfected into 2
million cells of control MEFs), 6 hrs later, total RNA were
extracted and the expression of IFNb and b-actin was analyzed by
RT-PCR.
(EPS)
Figure S9 Similar transfection efficiency of control MEF
and PI-MEF. A GFP expression plasmid was transfected into
control MEFs and PI-MEFs, 24 hrs later, the expression of GFP
was monitored by epifluorescent microscopy. Scale bar, 50 mm.
(EPS)
Figure S10 Expression of HA-tagged MAVS in control
MEFs and PI-MEFs. About 2 million control MEFs and PI-
MEFs were transfected with 8 mg of HA-MAVS expression
construct, cells were lysed after 24 hrs and the expression of
HA-MAVS was monitored by western blot with an anti-HA
antibody. A non-specific (N.S.) band serves as the loading control.
(EPS)
Figure S11 Treating PI-MEFs with ribavirin partially
restores the induction of IFNb expression. Control PI-
MEFs and PI-MEFs pretreated with ribavirin (25 mg/ml) for a
week were infected with a new dose of SeV for 6 hrs. Total cellular
RNA was extracted, and the expression of IFNb, SeV NP and b-
Actin was analyzed by RT-PCR.
(EPS)
Figure S12 Over-expression of Stat1 did not induce IFNb
in PI-MEFs. Control MEFs and PI-MEFs were transfected with
an expression construct for Stat1. 24 hrs later, total RNA were
extracted for RT-PCR analysis of IFNb, IRF7 and b-Actin
expression.
(EPS)
Figure S13 Diagram showing proposed model of IRF3
inactivation during acute and persistent Sendai virus
infections. Left: During acute virus infection, the primary
mechanism of IRF3 inactivation is proteolytic degradation, which
leads directly to the post-induction turn-off of IFNb expression.
Although the ubiquitin-proteosome pathway plays an important
role in IRF3 degradation, other unknown but inducible protease(s)
(or factors involved in the activation of these proteases) also
contribute significantly to IRF3 degradation. In fact, CHX has a
larger effect on IRF3 levels than proteosome inhibitors, suggesting
that the E3 ligase targeting IRF3 for degradation may also be
inducible. Alternatively, it is possible that phosphorylated IRF3
can be inactivated by an inducible phosphatase and then exported
to the cytoplasm. Whether IRF3 de-phosphorylation is required
for its degradation is not clear. Right: During persistent SeV
infection, the viral V protein directly inhibits IRF3 activity.
Binding of the V protein to IRF3 could interfere with its DNA
binding activity (as diagramed), or block its interaction with other
co-activators (not diagramed), thus inhibiting IFNb gene activa-
tion. Our data do not exclude the possibility that a labile host
factor (labile factor X) also inhibits IRF3 activity in persistently
infected cells. Both the V protein and the putative labile factor X
inactivate IRF3 by inhibiting its transcriptional activity, not
necessarily leading to degradation.
(EPS)
Table S1 Sequences of primers used in this study.
(DOC)
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